Natco Pharma files FY26 annual report, schedules AGM for September 30
- Natco Pharma Ltd filed its annual report for FY26 with BSE and NSE
- The 43rd AGM is scheduled for September 30, 2026, at 11:00 am
- The meeting will be held via video conferencing as per SEBI regulations
- The annual report is accessible on the company's investor relations page
*this image is generated using AI for illustrative purposes only.
Natco Pharma Limited has filed its annual report for the financial year 2025-26 with the Bombay Stock Exchange and the National Stock Exchange. The filing accompanies the notice for the company’s 43rd Annual General Meeting (AGM).
The AGM is scheduled to take place on Wednesday, September 30, 2026, at 11:00 am. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means, in compliance with Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Filing Details
The annual report is available on the company’s investor relations website. Ch. Venkat Ramesh, Company Secretary and Compliance Officer, signed the disclosure letter dated September 4, 2026.
| Detail | Information |
|---|---|
| Financial Year | FY26 |
| AGM Date | September 30, 2026 |
| AGM Time | 11:00 am |
| Mode | Video Conferencing / OAVM |
| Regulatory Reference | SEBI LODR Regulation 34(1) |
The document serves as a formal notification to the exchanges regarding the availability of the annual report for shareholder review ahead of the general meeting.
Historical Stock Returns for Natco Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.28% | +1.86% | -4.35% | -14.91% | -1.63% | 0.0% |
How is Natco Pharma expected to allocate its FY26 capital expenditures, particularly regarding R&D investments for its generic and specialty drug pipeline?
What strategic initiatives will management highlight at the AGM to address potential pricing pressures in key international markets like the US and Europe?
Are there any pending regulatory approvals or patent litigation outcomes that could significantly impact Natco's revenue growth trajectory in FY27?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
